Printer Friendly

LEDERLE LABORATORIES: FIRST MAJOR GENERIC CHOLESTEROL-REDUCING AGENT PROVIDES LOWER-COST TREATMENT OPTION FOR MILLIONS OF PATIENTS

 -- Availability of Lederle Laboratories' Gemfibrozil Could Save
 U.S. Health Care System Millions of Dollars --
 WAYNE, N.J., Oct. 6 /PRNewswire/ -- For the first time, a lower-cost therapeutic alternative is available for some of the approximately 2.5 million American patients who currently take branded cholesterol- lowering medications -- such as Parke-Davis' Lopid(R) -- and the physicians who treat them. Lederle Laboratories has received Food and Drug Administration (FDA) approval to market Gemfibrozil Tablets, the first major generic alternative to Parke-Davis' Lopid. Gemfibrozil is as safe and effective as Lopid, but is priced less than the branded product.
 A switch by the current one-half million Lopid patients in the United States to Lederle's Gemfibrozil could result in a potential annual savings of $100 to each individual, and over $50 million to the U.S. health care system. Lopid was the second-largest selling cholesterol modifying agent in the United States in 1992.
 "Lederle's Gemfibrozil is an excellent example of a pharmaceutical that fits very well with health care reform's focus on cost-effective treatment and disease prevention. Gemfibrozil helps control cholesterol, and therefore can contribute to the prevention of serious cardiac disease," said Frank Condella, vice president and general manager of Lederle Standard Products. "Lederle Standard Products is dedicated to providing patients in the U.S. with high-quality, low-cost generic alternatives, such as Gemfibrozil."
 Lederle's Gemfibrozil is used as adjunctive therapy to diet to treat adult patients with very high elevations of serum triglyceride levels, and to reduce certain patients' risk of developing coronary heart disease. Gemfibrozil will be supplied in 600 mg tablets in unit-of- issue bottles of 60 and bulk pharmacy packages of 500.
 Gemfibrozil joins the existing line of Lederle Standard Products, which includes recently approved generic versions of the antihypertensives Cardizem(R) (Diltiazem) and Tenormin(R) (Atenolol) and the non-steroidal anti-inflammatory drug (NSAID) Orudis(R) (Ketoprofen). Additionally, Lederle plans to launch generic versions of two of the largest branded products to ever come off patent; the anti-anxiety agent Alprazolam (Xanax)(R), which goes off patent Oct. 19, 1993 and the NSAID Naproxen (Naprosyn)(R), which goes off patent Dec. 21, 1993.
 Lederle Standard Products generics are manufactured according to the same rigorous manufacturing, quality control, regulatory and compliance standards that have characterized Lederle branded pharmaceuticals for several decades. The Lederle Standard Products label, established almost 20 years ago, now represents generic alternatives for more than 60 chemical entities and in excess of 200 package styles. Lederle Laboratories, a division of American Cyanamid Company (NYSE: ACY), is a research-intensive organization that manufactures and markets worldwide a broad range of healthcare products, including ethical pharmaceuticals, generics, vitamins and nutritionals.
 -0- 10/6/93
 /CONTACT: Pat Fiaschetti, 201-831-4684, for Lederle Laboratories/
 (ACY)


CO: Lederle Laboratories ST: New Jersey IN: MTC SU: PDT

SH-CK -- NYFNS2 -- 9161 10/06/93 07:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 6, 1993
Words:469
Previous Article:POWER OF THE PEN IS EVEN GREATER IN HIGH-TECH AGE; NEW PEN LINE IS BADGE OF PERSONALIZED EXECUTIVE AUTHORITY
Next Article:BRAD BENNETT STUDIOS, MLB PLAYERS ALUMNI ASSOCIATION TO PRESERVE THE MEMORIES OF CLEVELAND STADIUM AND ARLINGTON STADIUM IN LITHOGRAPHS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters